Introduction
Two of the most important measurements of the efficacy of a new cancer treatment are response rate and response duration. Standard response criteria (RC) that can be determined objectively are required in order to directly compare studies of different treatments. These criteria should be simple and reproducible, and should include quality assurance measures that (1) confirm compliance with criteria for an objective response and (2) ensure the validity of a reported response rate. Standard criteria are important to create consistency within a study, between studies, and across studies reported in the literature.
Standard criteria exist for the evaluation of the clinical response in patients with solid tumors, chronic lymphocytic lymphoma (CLL) [1] , Hodgkin's disease (HD) [2] , and acute leukemias [3] . Historically, criteria for solid tumors developed by the World Health Organization (WHO) [4] and the Eastern Cooperative Oncology Group (ECOG) [5] were commonly used to evaluate response in non-Hodgkin's lymphoma (NHL) patients. A review of the literature confirms that a wide variety of response definitions are in use in addition to the WHO and ECOG standards ( Table 1) . Many of these definitions use modifications of the WHO and ECOG criteria. Recently, specific criteria have been established for the evaluation of response in patients with NHL [6] .
Generally, investigators define a complete response (CR) as the 'complete disappearance' of disease and a partial response (PR) as a ^50% reduction in tumor mass. However, the definition of 'complete disappearance' varies. Parameters required for patients to be considered free of disease (complete response) have included the normalization of the following: complete blood count (CBC); clinical and radiologic findings; and lymph node (LN), spleen, and liver size. Additionally, the lack of bone marrow (BM) involvement may be required. Investigators have required different tests to evaluate response, including physical examination (PE), LN or BM biopsy, radiologic assessment (computed tomography [CT] , X-ray, gallium), and CBC. Some investigators have set a minimal duration for the absence or reduction of disease before the response is confirmed [4, 5, [7] [8] [9] [10] [11] [12] [13] [14] [15] . In some, responses are reclassified retrospectively. Because of these variations, the efficacy of NHL anticancer agents must be carefully weighed in literature reports that do not clearly define RC. With no standard criteria, comparing the efficacy of different treatments is difficult.
In order to set objective, defined standards, a panel of lymphoma experts was convened to define RC to determined by two observations not < 4 [4] weeks apart
Eastern Cooperative Disappearance of palpable/radiographic Oncology Group disease for at least four weeks (ECOG) [5] > 50% decrease in the total tumor size of the ^ 25% increase in the size of one or more lesions which have been measured to measurable lesion(s), or the appearance of determine the effect of therapy by two new lesions observations ^ 4 weeks apart, no new lesions; no progression of lesions.
Hiddemann et al. [10] Cabanillasetal. [13] Redman et al. [7] Meyer et al [14] Velasquez et al. [15] Pigaditou et al [21] Freedman et al. [22] Zinzani et al. [23] Kay et al. [24] Hoffman et al. [25] Betticher et al. [26] Saez et al. [27] Press et al. [34] Gottlieb et al. [36] Brown et al. [37] Kwak et al. [38] Elimination of all disease ^ 4 weeks and normalization of blood counts evaluate efficacy in the pivotal trial of rituximab (Rituxan®, MabThera®). Using data from the pivotal trial, retrospective analyses examined variations of the original RC components to determine their effect on the overall response rate (ORR) or the duration of response (DR). The results of these analyses were used to refine standardized RC for NHL at an International Workshop conducted at the National Cancer Institute (NCI). A report from this workshop, that included RC for NHL, was recently published [6] . We applied both the original RC and the new RC to the data from the pivotal trial to examine the differences in response rates, DR, and time to progression (TTP), if any.
Patients and methods
After consultation with the FDA, a panel of three lymphoma experts (S. J. Horning, B. A. Peterson, B. D. Cheson) was convened in December 1995 and subsequently produced a consensus statement in which they denned RC for low-grade or follicular (LG/F) NHL [16] to be applied in the pivotal clinical trial of the anti-CD20 antibody rituximab. These RC were presented to the Biological Response Modifiers Advisory Committee (BRMAC) and were submitted to and accepted by the FDA [17] . These RC were also reviewed and endorsed by a group of European NHL experts that included Drs B. Coiffier, A. Hagenbeek, W. Hiddemann, R. Marcus, T. Lister, A. Gianni, and J. Garcia-Conde [18] . The RC included response classifications, measures of duration, definitions for measurable lesions and measurable disease, procedures for lesion measurement, and a quality assurance process for response data.
After RC were established, a procedure for evaluating patients in the pivotal trial and applying these RC was initiated. In the pivotal trial, 166 patients with refractory or relapsed LG/F NHL received four weekly 375 mg/m 2 infusions of rituximab [19] . The principal investigator completed a case report form that included a judgement of clinical response based on the original RC. The sponsor reviewed both the case report forms and all tumor measurements for adherence to the guidelines set in the protocol and made an assessment of clinical response based on the RC. Then, an independent audit of CT scans for all patients exhibiting a 40% or greater reduction in overall tumor size was conducted as a quality assurance measure and as confirmation of the clinical investigator's assessment of response. A 'Lymphoma Expert's Confirmation of Response' panel (LEXCOR) was established that included six hematologists/oncologists and three radiologists, all recognized lymphoma experts and all third party to IDEC Pharmaceuticals Corporation. The LEXCOR panel conducted a blinded audit of CT scans at baseline, onset of response, and confirmation of response. They were blinded to the site's and the sponsor's classification of response and tumor measurements. CT scans of the neck, chest, abdomen, and pelvis were available for evaluation. All measurable lesions were identified and then measured bidimensionally with calipers. The sum of the products of the greatest perpendicular diameters (SPD) of all measurable lesions and the percent change from baseline were calculated. Clinical data and nonmeasurable lesion information were also reviewed, and a response classification was assigned.
We performed a retrospective analysis of these multiple measurements and other response data to determine whether applying the original rigorous criterion for normal LN size (^1.0 x 1.0 cm) and two alternative normal LN criteria (^1.5 x 1.5 cm and ;£ 2.0x2.0 cm) renders different ORR (CR and PR) and/or DR. Also, the original criteria require a confirmatory evaluation at ^ 28 days after the first evidence of response. We analyzed whether removing this requirement changed the CR rate. An evaluation of different progressive disease (PD) definitions was also conducted. The original criteria define PD as a ~z 50% increase in the SPD of all lesions from nadir, while others use a > 25% increase in SPD. We evaluated the pivotal-study data to see if using the ^25% increase changed the DR for all responders. We further examined whether patients progressed primarily due to an increase in SPD or because new lesions developed. In addition, an analysis was conducted to examine how the number of LN examined affects the response rate. Data from the pivotal trial were analyzed to see if the ORR and/or DR were different when only the six largest lesions were measured versus measuring all lesions. A final analysis was performed to compare response rates, DR, and TTP from the pivotal trial of rituximab using the original RC and the RC that were recently published from the International Workshop. Appearance of any new lesion 50% increase in the size of previously involved sites > 50% increase in the greatest diameter of any previously identified node > 1 cm in its short axis or in the SPD of more than one node PR or nonresponder patients with: SPD increased by ^ 50% from nadir New lesions Abbreviations: CR -complete response; CRu -unconfirmed complete response; PR -partial response; SD -stable disease; RD -relapsed disease; PD -progressive disease; CT -computed tomography; SPD -sum of the products of the greatest perpendicular diameters; NHL -nonHodgkin's lymphoma. a Developed for the pivotal clinical trial of rituximab and used by LEXCOR [16] . b Standardized response classifications for NHL developed at an International Workshop conducted at the National Cancer Institute (NCI) [6] .
Results
The lymphoma expert panel produced a consensus statement that defined RC. The four original response classifications (CR, PR, SD, PD) are described in Table 2 . Measures of response duration were defined as TTP and DR. TTP is measured in either a responder or nonresponder from the date of first study treatment to the first date when progressive disease is documented. DR is measured in a responder from the date when a CR or PR is first noted to the first date at which progressive disease is observed. These RC recognize that anatomical structures, such as LN, may not disappear completely on CT scans but must be substantially reduced for the patient to be classified as a CR. Thus, all measurable lesions must be measured bidimensionally with calipers at baseline. The first measurement is the longest measurable span of the lesion and the second measurement is the longest measurable span perpendicular to the first. The size of the lesion is the product of these two measurements. The products of all measurable lesions are added together for the SPD. If only one lesion is measurable, it must be ^ 2 cm in its longer diameter. The extent of disease is measurable if the patient has one or more clearly demarcated lesions, that is, a lesion with clearly defined margins that can be measured in centimeters. Skin lesions should be documented by photography and each measurable lesion should be consistently measured bidimensionally for the duration of the study.
Of 166 intent-to-treat patients in the pivotal trial of rituximab, 90 patients exhibited at least a 40% reduction in tumor size as assessed by the investigator (treating physician). These 90 patients' CT scans (about 5000 films) were evaluated by the LEXCOR group and response classifications were assigned using the original response classifications. Eighty patients were classified as responders by LEXCOR (10 CR and 70 PR). In 74 cases, the investigator and the sponsor both classified the patient as a responder for a three-way concordance rate of 93% (74 of 80) [16] . In 77 of the 80 cases, the investigator classified the patient as a responder for a two-way (investigator and LEXCOR) concordance rate of 96% (77 of 80). Ninety patients were classified as responders by the investigator (27 CR and 63 PR). In 77 cases, LEXCOR also classified the patient as a responder for a two-way (LEXCOR and investigator) concordance rate of 86% (77 of 90). In summary, the investigatordetermined response rate was 54% (90 of 166) while the LEXCOR-determined response rate was 48% (80 of 166). The response classification of LEXCOR superseded that of the investigator or the study sponsor. When the actual measurements obtained by the LEXCOR group were employed to assign responses using different threshold values for a normal lymph node, ^1.0 x 1.0 cm, sjl.5 x 1.5 cm, ^2.0 x 2.0 cm, the CR rates varied. Using a normal LN size measurement of ^ 1.0 x 1.0 cm resulted in a significantly lower CR rate than the other normal LN size measurements (^1.5 x 1.5 cm or ^2.0 x 2.0 cm); however, the ORR was not affected ( Table 3 ). The median DR decreased as the normal LN size was allowed to increase. The difference in median DR is significant between a normal LN size of < 1.0 x 1.0 cm and ^ 2.0 x 2.0 cm (P = 0.0219), but not between a normal LN size of ^ 1.0 x 1.0 cm and 1.5 x 1.5 cm (P = 0.0924). When the criterion requiring confirmation of response at ^ 28 days was not used, the CR rate increased from 6% to 12% using a normal LN size of «£ 1.0 x 1.0 cm; increased from 18% to 26% using a normal LN size of 1.5 x 1.5 cm; and increased from 28% to 36% using a normal LN size of ^ 2.0 x 2.0 cm (Table 4) . Additionally, the estimated median DR for intent-to-treat responders and the shape of the Kaplan-Meier curve did not change when the requirement for PD was decreased from a 50% increase in the SPD to a 25% increase in the SPD of all lesions (P = 0.94) (Figure 1 ). CR rate and DR were not affected when only the six largest lesions were measured, rather than all lesions.
Follow-up data of the pivotal study indicate that a minority of patients progress due to an increase in SPD only; most progress due to new lesions. By 11.8+ months of follow-up, 40 of the 80 responders were still ongoing. Of the 40 patients who had relapsed, 70% had progressed with new lesions. In the nonresponders, 54 patients had progressed, and of these, 57% had progressed due to new lesions.
When the new RC [6] were applied to the data from patients in the pivotal trial of rituximab, both a significantly higher CR rate (P -0.001) and a significantly lower PR rate (P = 0.001) were observed ( Table 5 ). In addition, the ORR is higher, although not significantly, when the new RC were used. The DR and TTP for CR patients were significantly shorter (P -0.009 and P = 0.010, respectively) with the new RC.
Discussion
The RC used to evaluate the efficacy of NHL treatments should accurately and objectively evaluate the presence or lack of disease, and should be consistent among trials to ensure comparability. The original RC used for the evaluation of the pivotal clinical trial of rituximab are conservative in their requirements for CR and PD, and do not include an unconfirmed complete response (CRu) classification ( Table 2) . The new criteria, recently published from the International Workshop conducted at the NCI, are a modification of the original criteria (Table 2, Figure 2) . The current analyses demonstrate the marked variability in response rates that occur with minor differences in response definitions, and serve to emphasize the need for standardized criteria, as well as the importance of endpoints such as progression-free survival and event-free survival.
Normalization or 'complete disappearance of disease,' according to the original RC, requires all LN to be < 1.0 x 1.0 cm in diameter. Analysis of the pivotal trial data showed that the number of complete responses would increase with increasing normal LN size. The new criteria require that LNs that were > 1.5 cm at baseline regress to < 1.5 cm in their greatest transverse diameter and that LNs that were > 1.1 cm and ^ 1.5 cm at baseline regress to < 1.0 cm in their greatest transverse diameter or regress by > 75% in the SPD.
A confirmatory evaluation for the response classification is also required in the original RC. The CR rate of the pivotal trial increased without the confirmation evaluation. The results of this analysis imply that, unless studies have equivalent confirmatory evaluations, their efficacy results are not comparable. Several NHL treatment studies did not require a confirmatory evaluation to classify a patient with a CR [20] [21] [22] [23] [24] [25] [26] [27] . Results from the pivotal study of rituximab may underestimate the CR rate compared with these published studies. The new RC do not require a response confirmation to be classified as a CR, CRu, or PR. A variety of definitions for PD are used in the literature (Table 1) . Some require progression in one lesion only, while others require progression across all lesions. The original RC require using the SPD of all lesions so that disease progression is not based on a small change in one small lesion. Different points of reference, such as baseline versus nadir, have been used to evaluate PD. These two different points of reference will change the onset of disease relapse, and thus the classification of PD. The lack of a clear definition for PD makes the comparisons between reported response durations impossible. The requirements for PD in the original RC are similar or stricter than current cooperative group RC that require a 25% increase in the SPD from baseline ( Table 6 ). The original RC define PD as a 50% increase in the SPD from nadir. Analysis showed that there is no difference in the DR between a 25% increase in the SPD and the original criterion (Figure 1 ). In addition, a 25% increase in size of small LNs may be difficult to detect and clinically unimportant.
The new RC use the same definition for PD as the original RC, except that only patients who achieved a PR or were nonresponders can be classified as PD. Patients who achieved a CR or CRu are classified with relapsed disease when a new lesion appears, the size of previously involved sites increase by ^ 50%, any previously identified node greater than 1 cm in its short axis increases by ^ 50% in the greatest diameter, or the SPD of more than one node increases by ^ 50%. Follow-up data of the pivotal study showed that, for the majority of patients, PD was determined based on the development of new lesions rather than on an increase in the size of existing lesions. Therefore, the comparisons between different criteria for PD may be overshadowed by the onset of new lesions.
Consequently, the frequency of follow-up evaluations is a more important factor in the determination of DR than the percent increase in lesion size. For the pivotal trial of rituximab, evaluations were conducted every three months for the first two years. In order to compare results between NHL studies, defined time points for re-evaluations must be established. The new RC recommend follow-up evaluations after completion of treatment at a minimum of every three months for two years, then every six months for three years, and then annually for five years. Patient evaluations should not be limited to known sites of disease, but should include a comprehensive evaluation of all nodal sites. Extensive evaluations may be more expensive, but are a necessary step to detect disease progression. Furthermore, the establishment of standardized increments for CT slices is necessary for results to be comparable. One issue that can be both complicated and controversial is the classification of a patient who has a LN that remains larger than normal, yet is not pathologically abnormal. Tumor masses in patients with NHL usually occur within a normal structure (i.e., a LN) that may shrink if treatment is effective, but may not reach normal size and appearance. A review of 241 patients treated for aggressive NHL at the NCI revealed that 40% (29 of 72) of the patients with an abdominal mass at diagnosis had a radiographically detectable residual mass at clinical CR [28] . Residual masses persist for a variety of possible reasons: tumor cells are killed but the stromal component remains intact, a reactive inflammatory and fibrotic process occurs in response to tumor cell death, or a tendency for intra-abdominal and particularly mesenteric structures to develop desmoplasia [28] . This remaining mass may not affect the patient's DR.
One study reported that the time to relapse was not different between patients with or without a fibronecrotic mass [29] . Thus, it is possible for a patient to meet all the criteria of a CR except that a single node remains abnormal in size. Should this patient be classified as a CR? A number of proposed classifications have been suggested: CRn (near complete response), CRu (uncertain/unconfirmed complete response), CCR (clinical complete response), and CR with a residual abnormality. Some investigators suggest that a large abdominal or mediastinal mass that undergoes a ^ 50% regression and stabilizes for at least two to four months should not prevent classification of a patient as a CR provided all other measurable disease shows a CR [28, [30] [31] [32] . Others suggest that a CR classification should be limited to those patients showing an overall regression of ^ 75% in initial tumor masses [6, 29] .
A classification of CR with a residual mass is important in intermediate-or high-grade NHL because these patients may actually be cured. LG/F NHL patients in the pivotal trial who had a residual lesion after treatment were not classified as complete responders. Because no cure exists for LG/F NHL patients, the ORR is a more appropriate measure of efficacy than CR rate alone in these patients. The new RC include a CRu classification for patients who have a residual LN mass > 1.5 cm in its greatest transverse diameter that has regressed by > 75% in the SPD. In addition, individual nodes that were previously confluent must have regressed by > 75% in their SPD compared with the size of the original mass. Patients with indeterminate bone marrow would also be classified as a CRu.
A review of the literature revealed that terminology used to describe end point measurements varies among NHL studies (Figure 3 ). Several terms define the period between study entry or treatment and disease progression, relapse, or treatment-related death [6, 9, 29, 33] . Additional terms are used to describe the period from response to disease progression or relapse [5, 6] . Different variations of survival have also been defined [6, 10, 29, 33, 34] . Onset of response is defined as the time between initiation of therapy and the first determination of PR or CR [5] . Measurements of DR, relapse-free survival, and disease-free survival all rely on the time of response and time of progressive disease onset. Both of these timepoints are variable within a study and across studies because they depend on when evaluations are conducted, and the timing of CT scans may vary between protocols. Some protocols require CT scans every three months while others wait as long as eight months for the first scan. TTP, time-to-treatment failure, failure-free survival, and freedom from relapse all begin with a fixed timepoint (study entry, start of treatment, or end of treatment). Thus, only one variable measurement exists in the calculation, the onset of progression. For study results to be comparable, this end point measurement must be standardized by specifying a timepoint when all patients will be evaluated.
When comparing efficacy between studies, it is necessary to eliminate as much variability as possible. The first option should be to use measurements that start at study entry and therefore have only one variable date. For the pivotal trial of rituximab, TTP was used. The new RC recommend using overall survival or time-totreatment failure. Using measurements that start with response should be the second option because of the additional variability. DR was used in the pivotal trial, while the new RC recommend DR and disease-free survival. This second option would require establishing defined evaluation periods. CT scans were obtained for patients in the pivotal trial of rituximab at three months and repeated every three months for the first year, then every six months for the next two years, and then yearly for the remaining responders. The new RC recommend follow-up evaluations after completion of treatment at a minimum of every three months for two years, then every six months for three years, and then annually for five years. With fixed evaluation points, the DR or disease-free survival between clinical trials can be compared.
The number of lesions measured for each study should be clearly defined. For the pivotal trial of rituximab, all lesions were measured to evaluate response. The new RC recommend the measurement of the six largest dominant nodes or nodal masses. Although results from the retrospective analyses revealed that the number of LNs measured did not affect the CR rate and DR with this data, it is still important to establish consistency between studies. The possibility of both intraobserver and interobserver variability in lesion measurements has been reported [35] . The fewer number of lesions measured, the more small differences in measurements are magnified. Also, it may be difficult for the radiologist to identify lesions that were measured at earlier timepoints. Thus, measuring all lesions would eliminate the possibility for error.
Because the original RC include a more stringent definition for CR and require a confirmation of response at ^28 days, the published results from the pivotal trial of rituximab underestimate the number of complete responders when compared to other NHL studies in the literature. When the data from the pivotal trial were analyzed with the new RC, a significantly higher CR rate and significantly shorter DR and TTP were observed.
In addition to the recent recommendations made by the International Workshop, it is important that response data, particularly from phase III or pivotal trials, be audited for quality assurance. Auditing confirms compliance with the objective RC and ensures that the resulting response rate is valid as a primary efficacy parameter and as a basis for approval of a new anticancer agent. Even the best RC need to be applied rigorously. A loose application of the strictest criteria may result in an inflated response rate.
